An Interactive Annotated World Bibliography of Printed and Digital Works in the History of Medicine and the Life Sciences from Circa 2000 BCE to 2024 by Fielding H. Garrison (1870-1935), Leslie T. Morton (1907-2004), and Jeremy M. Norman (1945- ) Traditionally Known as “Garrison-Morton”

16061 entries, 14144 authors and 1947 subjects. Updated: December 10, 2024

Permanent Link for Entry #16422

  • 14111

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

New Eng. J. Med., 344, 1031-1037, 2001.

The authors showed that the experimental drug (STI571) Imatinib, sold under the brand names Gleevec and Glivec,
1) was well tolerated and had very significant antileukemic activity in patients with chronic myeloid leukemia (CML). 
2) Adverse effects were minimal.
3) Complete hematologic responses were observed in 53 of 54 pts. treated with doses of 300 mg. or more. Cytogenetic responses occurred in 29, and 7 of those had complete cytogenetic remissions.
4) At the end of the paper they stated, “These results show that the BCR-ABL tyrosine kinase is critical to the development of CML and demonstrate the potential for the development of anticancer drugs based on the specific
molecular abnormality in a human cancer. “

Order of authorship in the original publication: Drucker, Talpaz, Resta. Full text available from nejm.org at this link.

(Thanks to Juan Weiss for this reference and its interpretation.)



Subjects: ONCOLOGY & CANCER › Leukemia
Permalink: historyofmedicine.com/id/16422